Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAKSZW)

• Drug Name: REGN4336 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMAKSZW

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[3]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[4]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[5]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[6]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[7]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[8]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[9]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[10]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[11]

Drug(s) Targeting Glutamate carboxypeptidase II (GCPII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capromab	DMHERIJ	Prostate cancer	2C82.0	Approved	[12]
PSMA-11 Ga-68	DMWLTU2	Diagnostic imaging	N.A.	Approved	[13]
Lutetium Lu-177 vipivotide tetraxetan	DMQ0IZ6	Prostate cancer	2C82.0	Approved	[14]
177-Lu-PSMA-617	DMX178V	Prostate cancer	2C82.0	Phase 3	[15]
BAY 2315497	DMUHH2G	Prostate cancer	2C82.0	Phase 3	[16]
J 591 Lu-177	DM9XKJU	Prostate cancer	2C82.0	Phase 2	[17]
G-202	DMQR9I8	Adenocarcinoma	2D40	Phase 2	[18]
ATL101	DMYAQV2	Influenza virus infection	1E30-1E32	Phase 2	[19]
99mTc-MIP-1404	DML4GU1	Prostate cancer	2C82.0	Phase 2	[20]
MLN-591RL	DMJHVZC	Prostate cancer	2C82.0	Phase 2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate carboxypeptidase II (GCPII)	TT9G4N0	FOLH1_HUMAN	Not Available	[1]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Not Available	[1]

References

• [1] ClinicalTrials.gov (NCT05125016) Phase 1/2 Study of REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
• [2] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [3] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [4] Clinical pipeline report, company report or official report of Genmab.
• [5] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [6] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [7] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [8] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [9] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [10] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [11] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
• [12] Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [14] [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8.
• [15] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus. 2020 Jun 30;12(6):e8921.
• [16] ClinicalTrials.gov (NCT03724747) Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health.
• [17] Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91.
• [18] National Cancer Institute Drug Dictionary (drug id 666090).
• [19] Clinical pipeline report, company report or official report of Atlab pharma.
• [20] 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76.
• [21] Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015 Apr 29;5:28.